European Pharmaceutical Review

JULY 4, 2024

In the US, botanical dietary supplements can be sold without US Food and Drug Administration (FDA) approval, 1 prompting many vendors to promote the use of botanical products as dietary supplements , 2 rather than pursue a path of regulatory approval. 3 Is two too few?

Marketing 103

Marketing Food and Drug Administration Medicine Prescription 103

PM360

OCTOBER 28, 2022

Shepherding a new drug to market is a long, expensive, and uncertain process. billion dollars to bring a new drug from discovery to regulatory approval and market launch. Approval success rates of drug candidates are between 10%–20% in the United States, the European Union, and Japan. in 2010 to only 1.9%

Pharma 105

Pharma Food and Drug Administration Medicine Government 105

Pharmaceutical Technology

APRIL 27, 2023

Pompe Disease, also known as glycogen storage type II, is a rare inherited lysosomal disorder caused by a deficiency of enzyme acid alpha-glucosidase (GAA) leading to the accumulation of glycogen in skeletal and cardiac muscles. Sanofi markets avalglucosidase alfa as Lumizyme in the US to treat LOPD since its approval in 2010.

Food and Drug Administration 52

Food and Drug Administration Food Marketing Medicine 52

Pharmaceutical Technology

MAY 18, 2023

Other processes include direct-to-patient (DtP) shipments of drugs and other supplies to a patient’s home, as well as in-home care with mobile nurses. Further analysis shows that low accrual rates have been the most common trial termination reason from 2010 to 2021, comprising 25.4% of all terminated trials.

Recruitment 52

Recruitment Food and Drug Administration Patients Media 52

World of DTC Marketing

APRIL 7, 2022

The seventh leading cause of death in the United States, diabetes costs $327 billion in medical costs and lost work and wages. Launch prices of new cancer drugs in the U.S. Food and Drug Administration (FDA). billion estimated cumulative spending on the new oral targeted cancer drugs by the end of 2018.

Healthcare 215

Healthcare Healthcare Food and Drug Administration Government 215

PM360

NOVEMBER 21, 2024

Prior to that, he was named Lead Independent Director in 2019 after serving as a director of the company since 2013. He was Executive VP and President of Merck’s Global Human Health Division from 2010 to 2019. Adam is an ethical leader who leads his business to serve the needs of patients and advance healthcare globally.

Ethics 59

Ethics Food and Drug Administration Marketing Leads 59